Clinical Trials Directory

Trials / Completed

CompletedNCT02107183

Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
500 (actual)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether, as compared with the Venturi mask, a nasal, high-flow oxygenation device (Optiflow) may reduce the extubation failure rate in patients needing oxygen therapy after extubation.

Detailed description

This study compares the effects of two devices for oxygen therapy, the nasal, high-flow (Optiflow, intervention) and the Venturi mask (control), on the outcome of extubation. Available data suggest that Optiflow can improve oxygenation and patient's comfort in critically ill patients after extubation. The study hypothesis is that Optiflow may reduce the extubation failure rate in these patients. In the intervention group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive high-flow oxygen through nasal cannula (Optiflow, Fisher \& Paykel Healthcare Ltd., New Zealand) after extubation. The oxygen concentration (FiO2) will be set to reach an oxygenation target similar to control patients (see below), while the gas flow rate will be set at 50 L/min. In the control group, patients fulfilling inclusion criteria and not presenting any of the exclusion criteria will receive oxygen through a standard Venturi mask after extubation. The FiO2 will be set to obtain a arterial oxygen saturation (SpO2) between 92% and 98% (or between 88% and 95% in hypercapnic patients). Further FiO2 modifications will be performed by the attending physicians to meet the oxygenation target.

Conditions

Interventions

TypeNameDescription
DEVICEOptiflow (Fisher & Paykel Healthcare)This device delivers high-flow oxygen through nasal cannula
DEVICEVenturi maskThis device delivers low-flow oxygen at predetermined concentrations

Timeline

Start date
2014-06-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2014-04-08
Last updated
2017-07-21

Locations

14 sites across 4 countries: France, Greece, Italy, Spain

Source: ClinicalTrials.gov record NCT02107183. Inclusion in this directory is not an endorsement.